Sunday, November 7, 2021
- 8:30AM-10:30AM
-
Abstract Number: 0674
A Behavioral Intervention to Improve Gout Outcomes in African Americans with Gout: A 12-month Multicenter, Randomized Controlled Trial
Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)- 8:30AM-10:30AM
-
Abstract Number: 0600
A Cohort Study of Retention in Ambulatory Lupus Care Among Medicare Patients with SLE-related Hospitalizations
Healthcare Disparities in Rheumatology Poster (0594–0622)- 8:30AM-10:30AM
-
Abstract Number: 0853
A Combined Patient Registry and Biobank Laboratory Information System for Prospective Multisite Chronic Rheumatic Disease Research Using REDCap
Research Methodology Poster (0846–0854)- 8:30AM-10:30AM
-
Abstract Number: 0729
A Multicenter, Observational, Extension Study Evaluating the Safety, Tolerability, and Efficacy of a Single Lorecivivint Injection in Knee OA Subjects
Osteoarthritis – Clinical Poster II (0723–0738)- 8:30AM-10:30AM
-
Abstract Number: 0570
A Narrowed, but Persistent Mortality Gap: A National, Matched Cohort Study in U.S. Veterans with Rheumatoid Arthritis from 2000-2017
Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)- 8:30AM-10:30AM
-
Abstract Number: 0733
A New Wearable Transcutaneous Electrical Nerve Stimulation Device (actiTENS®) Is More Efficient and Better Tolerated Than Weak Opioids in the Treatment of Knee Osteoarthritis Pain
Osteoarthritis – Clinical Poster II (0723–0738)- 8:30AM-10:30AM
-
Abstract Number: 0845
A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study
RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)- 8:30AM-10:30AM
-
Abstract Number: 0867
A Proteomic/Transcriptomic Analysis Associates with Subclinical Vascular Disease in Systemic Lupus Erythematosus
SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)- 8:30AM-10:30AM
-
Abstract Number: 0847
A Psychometric Analysis of the Self-Efficacy for Managing Chronic Disease Scale in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study
Research Methodology Poster (0846–0854)- 8:30AM-10:30AM
-
Abstract Number: 0819
A Real-World 2-Year Prospective Study of Medication Tapering in Patients with RA in Sustained Remission in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)- 8:30AM-10:30AM
-
Abstract Number: 0805
A Real-world Prospective Observational Study of the Effectiveness of Golimumab in Adult Greek Patients with RA, PsA and Axial SpA and Inadequate Response to Initial TNFα Inhibitor Therapy
RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)- 8:30AM-10:30AM
-
Abstract Number: 0656
A Survey Based Descriptive Study to Assess the Quality of Sleep in Rheumatic Patients
Measures & Measurement of Healthcare Quality Poster (0623–0659)- 8:30AM-10:30AM
-
Abstract Number: 0658
ACCORD: A Novel Rheumatology Transition Clinic Structure for Adolescent and Young Adult Patients with Childhood Onset Rheumatic Disease
Measures & Measurement of Healthcare Quality Poster (0623–0659)- 8:30AM-10:30AM
-
Abstract Number: 0667
Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk